Bioptic telescope aids drivers with AMD

Article

Drivers with age-related macular degeneration (AMD) who used a small, spectacle-mounted bioptic telescope reported fewer self-imposed driving restrictions when compared with drivers with AMD who did not use the telescope. Alex R. Bowers, PhD, MCOptom, of the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, noted that drivers with AMD who used the telescope drove greater distances and to more paces and reported fewer difficulties in potentially challenging situations, such as night driving, heavy traffic, or rain.

Drivers with age-related macular degeneration (AMD) who used a small, spectacle-mounted bioptic telescope reported fewer self-imposed driving restrictions when compared with drivers with AMD who did not use the telescope. Alex R. Bowers, PhD, MCOptom, of the Schepens Eye Research Institute, Department of Ophthalmology, Harvard Medical School, Boston, noted that drivers with AMD who used the telescope drove greater distances and to more places and reported fewer difficulties in potentially challenging situations, such as night driving, heavy traffic, or rain.

The bioptic telescope magnifies distant objects; drivers with this device are taught to use their carrier lens most of the time and glance through the telescope for only a few seconds at a time to read a road sign or street name. Drivers with moderately reduced visual acuity are allowed to use this device in about 36 states.

Changes in driving habits mentioned by individuals using the bioptic telescope could be due to their improved navigational skills. Being better able to read road signs, drivers are more willing to drive greater distances and explore new areas. In addition, some states require drivers who use the telescope to undergo additional behind-the-wheel training. This may enhance their skills and give them the confidence to drive more. However, an unresolved question is whether the bioptic telescope leads to overconfidence and risky driving behavior.

The study included drivers with reduced visual acuity, with and without central field loss, who had recent experience driving with the bioptic telescope. This group included 27 individuals with AMD. In all, 115 individuals were interviewed by phone. Data on driving habits for individuals with AMD were compared with those from an earlier study that included information on drivers with AMD who did not use the telescope.

Analyzing telescope usage habits, Dr. Bowers reported that drivers with central field loss reported spending a greater proportion of their driving time looking through the telescope than those without central field loss. This was more likely due to their visual defect and dependence on the device than to their age, Dr. Bowers added.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
© 2025 MJH Life Sciences

All rights reserved.